Expanding the Spectrum of HER2-Positivity for Breast Cancer Care: Implications of HER2-Low Status

Expanding the Spectrum of HER2-Positivity for Breast Cancer Care: Implications of HER2-Low Status

Tuesday, December 6, 2022 in San Antonio, TX
Dinner -- San Antonio Marriott Rivercenter, 7:00 PM CT
Salons ABF

Agenda

Welcome, Overview, Audience Polling Questions

  • The Evolving World of HER2 in Advanced Breast Cancer
  • Biomarker Testing and Nuances in HER2-expressing Breast Cancer
  • Available Treatments and Emerging Options for in HER2-Low/Negative Breast Cancer
  • Adverse Event Identification/Management

Audience Question and Answer Session

Faculty

Program Director
Nadia Harbeck, MD, PhD

Professor
Head, Breast Center
University of Munich (LMU)
Munich, Germany

Faculty
Komal Jhaveri, MD

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Assistant Professor of Medicine
Weill Cornell Medical College
New York, New York

Faculty
Heather McArthur, MD, MPH

Associate Professor
Department of Medicine
Komen Distinguished Chair in Clinical Breast Cancer
Clinical Director Breast Cancer Program
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to individualize the care of patients with HER2-low status breast cancer.

Target Audience
This program is intended for physicians, pathologists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the science and emerging clinical evidence on HER2 targeted agents in HER2-low breast cancer
  • Outline ways to improve communication and coordination among pathologists, oncologists, and other members of the cancer care team when discussing HER2 test results in patients with breast cancer
  • Plan individualized treatment strategies for patients with HER2-low metastatic breast cancer, considering available clinical evidence and expert recommendations
  • Manage adverse events associated with different HER2 targeted antibody drug conjugates, including procedures to educate patients and optimize quality of life and efficacy of prescribed therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.